Details

Autor(en) / Beteiligte

• Grobman, William A., MD, MBA
• Thom, Elizabeth A., PhD
• Spong, Catherine Y., MD
• Iams, Jay D., MD
• Saade, George R., MD
• Mercer, Brian M., MD
• Tita, Alan T.N., MD
• Rouse, Dwight J., MD
• Sorokin, Yoram, MD
• Wapner, Ronald J., MD
• Leveno, Kenneth J., MD
• Blackwell, Sean, MD
• Esplin, M. Sean, MD
• Tolosa, Jorge E., MD, MSCE
• Thorp, John M., MD
• Caritis, Steve N., MD
• Van Dorsten, J. Peter, MD

Titel

17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm

Ist Teil von

• American journal of obstetrics and gynecology, 2012-11, Vol.207 (5), p.390.e1-390.e8

Ort / Verlag

New York, NY: Mosby, Inc

Erscheinungsjahr

2012

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Objective We sought to evaluate whether 17 alpha-hydroxyprogesterone caproate (17-OHP) reduces preterm birth (PTB) in nulliparous women with a midtrimester cervical length (CL) <30 mm. Study Design In this multicenter randomized controlled trial, nulliparous women with a singleton gestation between 16 and 22 3/7 weeks with an endovaginal CL <30 mm (<10th percentile in this population) were randomized to weekly intramuscular 17-OHP (250 mg) or placebo through 36 weeks. The primary outcome was PTB <37 weeks. Results The frequency of PTB did not differ between the 17-OHP (n = 327) and placebo (n = 330) groups (25.1% vs 24.2%; relative risk, 1.03; 95% confidence interval, 0.79–1.35). There also was no difference in the composite adverse neonatal outcome (7.0% vs 9.1%; relative risk, 0.77; 95% confidence interval, 0.46–1.30). Conclusion Weekly 17-OHP does not reduce the frequency of PTB in nulliparous women with a midtrimester CL <30 mm.